Invivyd (IVVD) Total Current Liabilities (2020 - 2025)
Invivyd (IVVD) posted Total Current Liabilities of $34.2 million for Q4 2025, down 23.22% on a QoQ basis from $44.5 million in Q3 2025, and down 44.88% year-over-year from $62.0 million in Q4 2024.
Invivyd (IVVD) Total Current Liabilities (2020 - 2025) Analysis & Trends
Invivyd's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $34.2 million for Q4 2025.
- Quarterly Total Current Liabilities fell 44.88% year-over-year to $34.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.2 million (down 44.88% YoY) and the FY2025 annual result came in at $34.2 million, down 44.88% from the prior year.
- Total Current Liabilities was $34.2 million for Q4 2025 at Invivyd, down from $44.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $95.5 million in Q1 2022 and bottomed at $22.1 million in Q1 2023.
- A 5-year average of $47.7 million and a median of $44.5 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities surged 374.76% — and 2023, when it slumped 76.91%.
- Invivyd's Total Current Liabilities stood at $62.1 million in 2021, then tumbled by 59.67% to $25.0 million in 2022, then soared by 100.91% to $50.3 million in 2023, then gained by 23.23% to $62.0 million in 2024, then sank by 44.88% to $34.2 million in 2025.
- Business Quant data shows IVVD's Total Current Liabilities at $34.2 million in Q4 2025, $44.5 million in Q3 2025, and $44.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 289.60 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 34.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.16 Mn |
| Sep 30, 2025 | 44.50 Mn |
| Jun 30, 2025 | 44.45 Mn |
| Mar 31, 2025 | 49.60 Mn |
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.54 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.35 Mn |
| Dec 31, 2023 | 50.29 Mn |
| Sep 30, 2023 | 26.79 Mn |
| Jun 30, 2023 | 32.51 Mn |
| Mar 31, 2023 | 22.06 Mn |
| Dec 31, 2022 | 25.03 Mn |
| Sep 30, 2022 | 46.13 Mn |
| Jun 30, 2022 | 67.88 Mn |
| Mar 31, 2022 | 95.53 Mn |
| Dec 31, 2021 | 62.06 Mn |
| Sep 30, 2021 | 53.05 Mn |
| Jun 30, 2021 | 37.90 Mn |
| Dec 31, 2020 | 13.07 Mn |